Almutairi AR, McBride A, Slack M et al (2020) Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol 10:91
Article PubMed PubMed Central Google Scholar
Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872–2878
Article CAS PubMed Google Scholar
Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Ann Rev Pathol 16:223–249
Blidner AG, Choi J, Cooksley T et al (2020) Cancer immunotherapy-related adverse events: causes and challenges. Support Care Cancer 28:6111–6117
Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714–1768
Article CAS PubMed Google Scholar
Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426
Article CAS PubMed PubMed Central Google Scholar
Daniello L, Elshiaty M, Bozorgmehr F et al (2021) Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer. Front Oncol 11:703893
Article PubMed PubMed Central Google Scholar
Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M (2017) Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs 4:127–135
Article PubMed PubMed Central Google Scholar
Dudnik E, Moskovitz M, Rottenberg Y et al (2020) Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Oncoimmunology 10:1865653
Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New Engl J Med 375:1856–1867
Grangeon M, Tomasini P, Chaleat S et al (2019) Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer 20:201–207
Article CAS PubMed Google Scholar
Gülave B, Hew MN, de Groot JS et al (2021) High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors. ESMO Open 6:100–107
Hussaini S, Chehade R, Boldt RG et al (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – a systematic review and meta-analysis. Cancer Treat Rev 92:102–134
Khoja L, Day D, Wei-Wu Chen T et al (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377–2385
Article CAS PubMed Google Scholar
Kichenadasse G, Miners JO, Mangoni AA et al (2020) Multiorgan immune-related adverse events during treatment with atezolizumab. J Natl Compr Canc Netw 18:1191–1199
Article CAS PubMed Google Scholar
Kostine M, Mauric E, Tison A et al (2021) Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 157:474–484
Article CAS PubMed Google Scholar
Miura K, Sano Y, Niho S et al (2021) Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thorac Cancer 12:1983–1994
Article CAS PubMed PubMed Central Google Scholar
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. New Engl J Med 378:158–168
Article CAS PubMed Google Scholar
Rapoport BL, Anderson R, Cooksley T, Johnson DB (2020) MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer 28:6107–6110
Rose LM, DeBerg HA, Vishnu P et al (2021) Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors. Front Oncol 15:570752
Shankar B, Zhang J, Naqash AR et al (2020) Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol 6:1952–1956
Tang SQ, Tang LL, Mao YP et al (2021) The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8436 patients. Cancer Res Treat 53:339–354
Article CAS PubMed Google Scholar
Thompson JA, Schneider BJ, Brahmer J et al (2020) NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw 18:230–241
Article CAS PubMed Google Scholar
Thompson LL, Krasnow NA, Chang MS et al (2021) Patterns of cutaneous and non cutaneous immune-related adverse events among patients with advanced cancer. JAMA Dermatol 157:577–582
Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137
Article CAS PubMed Google Scholar
Yamaguchi A, Saito Y, Okamoto K et al (2021) Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis. Support Care Cancer 29:7747–7753
留言 (0)